OOIR: Observatory of International Research

Papers

(The H4-Index of JNCI-Journal of the National Cancer Institute is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Correction to: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	235
Vertical integration in oncology: what does it mean for patients with cancer?	170
Re: Deng and Heybati	159
Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer	145
The National Cancer Institute Funding of Global Research: Lessons Learned and Opportunities Going Forward	131
Response to Liu and Zhang	96
Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC	92
Long-term aspirin use and cancer risk: a 20-year cohort study	77
RE: Use of artificial intelligence for cancer clinical trial enrollment	73
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers	72
Method of primary breast cancer detection and the disease-free interval, adjusting for lead time	71
Evaluating a blood test for colon cancer screening: how simulation modeling can inform clinical policy making and research	70
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study	64
Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study	61
The Unrelenting Impact of Poverty on Cancer: Structural Inequities Call for Research and Solutions on Structural Determinants	58
Addressing Diversity, Equity, and Inclusion at the JNCI Journals	58
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination	57
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020	57
Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study	56
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment	55
Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities	54
Understanding risk factors for endometrial cancer in young women	53
Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort	51
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial	50
Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients	49

Medication–Associated Phthalate Exposure and Childhood Cancer Incidence	49
Impact of knowledge of human papillomavirus positivity on cervical cytology performance in Latin America	48
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer	48
Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report	48
Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas	46
Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study	46
Leisure-time physical activity after diagnosis and survival by cancer type: a pooled analysis	45
An Artificial Intelligence System for the Detection of Bladder Cancer via Cystoscopy: A Multicenter Diagnostic Study	45
Contribution of health insurance to racial and ethnic disparities in advanced-stage diagnosis of 10 cancers	45
Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study	45
The National Health Service-Galleri multi-cancer screening trial: explanation and justification of unique and important design issues	45
Urgent need to mitigate disparities in federal funding for cancer research	44
Optimizing public-private partnerships to support clinical cancer research	44
Association Between Medicaid Expansion Under the Affordable Care Act and Survival Among Newly Diagnosed Cancer Patients	42
Cancer control co-benefits of the climate-related provisions in the American Inflation Reduction Act	41
The triple effect of colorectal cancer screening: reducing deaths, government spending, and mortality disparities	41
Evaluating colonoscopy quality by performing provider type	41